Will Boston Scientific's Upcoming Launches Fuel the Next Growth Phase?

Boston Scientific expects global Electrophysiology growth to be flat in the second half of 2026 as competitive pressure intensifies after FARAPULSE captured about 80% of the U.S. AFib pulsed-field-ablation market. The company targets renewed U.S. EP momentum in 2H 2027 through FARAWAVE Ultra and an intracardiac-echocardiography entry, with FARAFLEX expected in 2028; PRECEDENT and SEISMIQ 4CE are also planned for 2027. Near-term sentiment remains pressured by a 55.4% 12-month stock decline, downward earnings-estimate revisions, above-industry valuation at 2.85x forward five-year price-to-sales, and a Zacks Rank #5 (Strong Sell).

Analysis

The investable read-through is not the launch pipeline but the timing mismatch: BSX faces near-term EP deceleration while its meaningful platform responses sit beyond the period in which consensus estimates must be defended. A high installed-base share in U.S. PFA makes incremental growth increasingly dependent on procedure expansion, pricing, and successful cross-selling into mapping/ICE rather than further share capture. That raises the probability of 1-3 quarter estimate de-risks and multiple compression if EP growth does not stabilize before the next major product cycle.

ABT is the clearest competitive beneficiary because an integrated PFA-plus-mapping workflow can reduce switching friction for EP labs already using EnSite. The relevant second-order signal is utilization: if hospitals standardize around a closed workflow, disposable catheter share can move faster than headline procedure volumes. BSX's future ICE entry also puts it into a market with entrenched incumbents, implying launch-related selling expense and potential price concessions before revenue contribution becomes material.

Contrarianly, the weakness may become attractive only if management demonstrates that flat EP growth is a temporary portfolio-gap issue rather than evidence of sustained PFA commoditization. RIVOS and coronary lithotripsy provide optionality, but neither should be capitalized into near-term estimates without disclosed adoption, reimbursement, and gross-margin data. Watch quarterly EP organic growth, U.S. PFA share, procedure volumes, and any reduction in FY guidance; these are more decisive than favorable early physician commentary.

Over 6-18 months, the key structural risk is that PFA becomes a lower-differentiation consumables market while mapping, imaging, and service ecosystems retain the economic profit pool. In that outcome, incumbent workflow owners such as ABT can sustain better attachment economics, and BSX's eventual platforms must win on clinical throughput or total-lab cost rather than novelty alone.

Key Decisions for Investors

• Maintain an underweight/short BSX versus ABT over the next 1-3 quarters; use a roughly dollar-neutral pair to isolate EP execution risk. Target a 10-15% relative move, with a stop if BSX reports reaccelerating EP organic growth above management's flat-growth framing for two consecutive quarters or raises full-year guidance.
• Add ABT on evidence of Volt adoption beyond initial sites, particularly disclosed EnSite X placements or EP growth above company baseline expectations. The catalyst window is the next two earnings cycles; risk is slower U.S. regulatory/commercial rollout or hospital capital-budget pressure limiting mapping-system upgrades.
• Do not underwrite BSX's 2027-28 launches into current earnings. Set an alert for disclosed launch timing, reimbursement, gross-margin impact, and early utilization for RIVOS and future EP platforms; absent these data, a long BSX is a valuation-reversion trade rather than a product-cycle trade.
• Avoid GMED as a direct expression of this thesis: its imaging update has limited economic linkage to BSX's EP competitive dynamics. Revisit only if management quantifies imaging-system orders, installed-base conversion, or procedure-related recurring revenue.